Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

Also called NCT05238519

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose screening
Phase
Phase 3
Enrolled
  • 257 participants (enrolled count) (from the registry)
Sponsor
Essentia Health (from the registry)
Registry
  • NCT NCT05238519
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05238519. Randomized; no masking; primary purpose screening. Start 2022-02-15 (actual); primary completion 2024-11-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
Acronym
ID-FH
Condition
Cholesterol, Elevated
Condition
Genetic Disease
Intervention (Behavioral)
Motivational interview (MI)
Lead sponsor
Essentia Health (class: other)
Collaborator
WHITESIDE Institute for Clinical Research (class: not stated)
Collaborator
Aspirus St. Luke's Hospital (class: not stated)

Record details

Record id
cardio:ct-nct05238519
Content hash
905607ab85d592c5bad4eb7cdce2502b8ff5682f00f0a478ff19da69be62891e